Showing results (11-20 of 105) with videos related to
Sort By:
Pageof 11
Magnetic Resonance in Medicine|August 1, 2012
Assessing the reproducibility of dynamic contrast enhanced magnetic resonance imaging in a murine model of breast cancerStephanie L Barnes, Jennifer G Whisenant, Mary E Loveless, et al.Molecular Biology of the Cell|January 10, 2014
CXCR4 drives the metastatic phenotype in breast cancer through induction of CXCR2 and activation of MEK and PI3K pathwaysTammy Sobolik, Ying-Jun Su, Sam Wells, et al.The Journal of Clinical Investigation|June 10, 2010
Conditional ablation of Ikkb inhibits melanoma tumor development in miceJinming Yang, Ryan Splittgerber, Fiona E Yull, et al.Journal of Shoulder and Elbow Surgery|October 23, 2021
Risk factors for degenerative, symptomatic rotator cuff tears: a case-control studyAmos Song, Damien Cannon, Peter Kim, et al.International Journal of Cancer|December 30, 2003
HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumorsElizabeth Half, Russell Broaddus, Kathleen D Danenberg, et al.Journal of Clinical Medicine|January 11, 2024
Incidence and Clinical Risk Factors of Post-Operative Complications following Primary Total Hip Arthroplasty: A 10-Year Population-Based Cohort StudyYen-Sheng Lin, Joshua J DeClercq, Gregory D Ayers, et al.Anesthesia and Analgesia|December 25, 2009
The diverse effects of vasopressors on the fetoplacental circulation of the dual perfused human placentaBeth H Minzter, Raymond F Johnson, Ray L Paschall, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 25, 2014
Should mesenteric tumor deposits be included in staging of well-differentiated small intestine neuroendocrine tumors?Raul S Gonzalez, Eric H Liu, JoAnn R Alvarez, et al.Cancer Immunology Research|November 12, 2020
Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor ImmunityJinming Yang, Chi Yan, Anna E Vilgelm, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Many patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapyOzden Altundag, David J Stewart, Frank V Fossella, et al.Pageof 11